Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology.
Targeting of antifibrotic drugs to hepatic stellate cells (HSC) is a promising strategy to block fibrotic processes leading to liver cirrhosis. For this purpose, we utilized the neo-glycoprotein mannose-6-phosphate-albumin (M6PHSA) that accumulates efficiently in HSC during liver fibrosis. Pentoxifylline (PTX), an antifibrotic compound that inhibits HSC proliferation and activation in vitro, was conjugated to M6PHSA. We employed a new type of platinum-based linker, which conjugates PTX via coordination chemistry rather than via covalent linkage. When incubated in plasma or in the presence of thiol compounds, free PTX was released from PTX-M6PHSA at a sustained slow rate. PTX-M6PHSA displayed pharmacological activity in cultured HSC as evidenced by changes in cell morphology and reduction of collagen I production. PTX-M6PHSA and platinum coupled PTX did not induce platinum-related toxicity (Alamar Blue viability assay) or apoptosis (caspase activation and TUNEL staining). In vivo distribution studies in fibrotic rats demonstrated specific accumulation of the conjugate in nonparenchymal cells in the fibrotic liver. In conclusion, we have developed PTX-M6PHSA employing a novel type of platinum linker, which allows sustained delivery of the drug to HSC in the fibrotic liver.
Gonzalo
Teresa
T
Department of Pharmacokinetics and Drug Delivery, Groningen University Institute for Drug Exploration, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. T.Gonzalo.Lazaro@rug.nl
Talman
Eduard G
EG
van de Ven
Anke
A
Temming
Kai
K
Greupink
Rick
R
Beljaars
Leonie
L
Reker-Smit
Catharina
C
Meijer
Dirk K F
DK
Molema
Grietje
G
Poelstra
Klaas
K
Kok
Robbert J
RJ
D000199:Actins / Q000032:analysis; D000818:Animals; D001682:Biological Availability; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D024042:Collagen Type I / Q000032:analysis; D016503:Drug Delivery Systems / Q000379:methods; D004789:Enzyme Activation / Q000187:drug effects; D008099:Liver / Q000737:chemistry / Q000166:cytology / Q000378:metabolism*; D008103:Liver Cirrhosis / Q000378:metabolism / Q000517:prevention & control; D008297:Male; D051379:Mice; D009130:Muscle, Smooth / Q000737:chemistry; D041681:NIH 3T3 Cells; D009944:Organoplatinum Compounds / Q000737:chemistry*; D010431:Pentoxifylline / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology; D010744:Phosphoric Monoester Hydrolases / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D013678:Technology, Pharmaceutical / Q000379:methods; D014018:Tissue Distribution
D000199:Actins; D024042:Collagen Type I; D009944:Organoplatinum Compounds; C023553:mannose-6-phosphatase; D010744:Phosphoric Monoester Hydrolases; C505409:Casp3 protein, mouse; C505410:Casp3 protein, rat; D053148:Caspase 3; D020169:Caspases; D010431:Pentoxifylline